Knoa Pharma LLC
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Knoa Pharma is a public health–focused pharmaceutical company dedicated to developing innovative, small molecule therapeutics that address significant unmet medical needs. We also seek to expand access to lifesaving opioid overdose reversal medications and affordable treatment for opioid use disorder at no profit.
We have a promising pipeline of novel compounds currently in clinical trials across multiple therapeutic areas. Sunobinop, an orally active nociceptin agonist, is being investigated in CNS disorders such as insomnia and alcohol use disorder, as well as the urologic conditions overactive bladder and interstitial cystitis. In oncology, Knoa is advancing tinostamustine, a dual acting DNA alkylator and pan-HDAC inhibitor designed to treat highly challenging diseases, including glioblastoma and a hematological and solid tumors. Tinostamustine was recently granted Orphan Drug status for the treatment of gliomas and has begun enrolling patients in the Phase 2/3 GBM AGILE trial.
Company HQ City:
Stamford
Company HQ State:
CT
Company HQ Country:
United States
Year Founded:
2026
Lead Product in Development:
Tinostamustine
CEO
Marc Kesselman
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
two
When you expect your next catalyst update?
November 2026
What is your next catalyst (value inflection) update?
completion of Phase 2 trial of sunobinop in alcohol use disorder
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}